<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO> FR89418-0079 </DOCNO><DOCID>fr.4-18-89.f2.A1078</DOCID><TEXT><ITAG tagnum="69"><ITAG tagnum="41">[Docket No. 89M-0043]</ITAG><ITAG tagnum="56">Meadox Medicals, Inc.; Premarket Approval of Stryker Dacron LigamentProsthesis </ITAG><ITAG tagnum="10"><T2>AGENCY: </T2>Food and Drug Administration.</ITAG><ITAG tagnum="10"><T2>ACTION: </T2>Notice.</ITAG><ITAG tagnum="10"><T2>SUMMARY: </T2>The Food and Drug Administration (FDA) is announcingits approval of the application by Meadox Medicals, Inc., Oakland, NJ,for premarket approval, under the Medical Device Amendments of 1976, ofthe Stryker<T4>#</T4> Dacron<T4>#</T4> Ligament Prosthesis. After reviewing the recommendation of theOrthopedic and Rehabilitation Devices Panel, FDA's Center for Devices andRadiological Health (CDRH) notified the applicant, by letter of December30, 1988, of the approval of the application.</ITAG><ITAG tagnum="10"><T2>DATE: </T2>Petitions for administrative review by May 18, 1989.</ITAG><ITAG tagnum="10"><T2>ADDRESS: </T2>Written requests for copies of the summary of safetyand effectiveness data and petitions for administrative review to the DocketsManagement Branch (HFA-305), Food and Drug Administration, Rm. 4-62, 5600Fishers Lane, Rockville, MD 20857.</ITAG><ITAG tagnum="10"><T2>FOR FURTHER INFORMATION CONTACT:</T2>Michael J. Blackwell, Center forDevices and Radiological Health (HFZ-410), Food and Drug Administration,8757 Georgia Ave., Silver Spring, MD 20910, 301-427-7156.</ITAG><ITAG tagnum="10"><T2>SUPPLEMENTARY INFORMATION: </T2>On August 5, 1985, Meadox Medicals,Inc., Oakland, NJ 07436, submitted to CDRH an application for premarketapproval of the Stryker<T4>#</T4> Dacron<T4>#</T4> Ligament Prosthesis. The device is a prosthetic ligament fabricatedfrom a combination of texturized and untexturized Dacron<T4>#</T4> yarns. The device consists of a knitted velour tube with a reinforcingcore made up of four woven tapes. The device is placed intra-articularlyby tibial and femoral attachments through bone tunnels. The device is indicatedfor use only as an intra-articular permanent replacement for the anteriorcruciate ligament (ACL) of the knee for skeletally mature patients whohave had at least one failed autogenous intra-articular reconstructionof their ACL.On January 22, 1988, the Orthopedic and Rehabilitation Devices Panel, anFDA advisory committee, reviewed and recommended approval of the application.On December 30, 1988, CDRH approved the application by a letter to theapplicant from the Acting Director of the Office of Device Evaluation CDRH.A summary of the safety and effectiveness data on which CDRH based itsapproval is on file in the Dockets Management Branch (address above) andis available from that office upon written request. Requests should beidentified with the name of the device and the docket number found in bracketsin the heading of this document. A copy of all approved labeling is available for public inspection at CDRH_contactMichael J. Blackwell (HFZ-410), address above. <ITAG tagnum="84">Opportunity for Administrative Review </ITAG>Section 515(d)(3) of the Federal Food, Drug, and Cosmetic Act (the act)(21 U.S.C. 360e(d)(3)) authorizes any interested person to petition, undersection 515(g) to the act (21 U.S.C. 360e(g)), for administrative reviewof CDRH's decision to approve this application. A petitioner may requesteither a formal hearing under Part 12 (21 CFR Part 12) of FDA's administrativepractices and procedures regulations or a review of the application andCDRH's action by an independent advisory committee of experts. A petitionis to be in the form of a petition for reconsideration under andSection;10.33(b) (21 CFR 1033(b)). A petitioner shall identify the form of reviewrequested (hearing or independent advisory committee) and shall submitwith the petition supporting data and information showing that there isa genuine and substantial issue of material fact for resolution throughadministrative review. After reviewing the petition, FDA will decide whetherto grant or deny the petition and will publish a notice of its decisionin the <T4>Federal Register</T4>. If FDA grants the petition, the notice willstate the issue to be reviewed, the form of review to be used, the personswho may participate in the review, the time and place where the reviewwill occur, and other details.Petitioners may, at any time on or before May 18, 1989, file with the DocketsManagement Branch (address above) two copies of each petition and supportingdata and information, identified with the name of the device and the docketnumber found in brackets in the heading of this document. Received petitionsmay be seen in the office above between 9 a.m. and 4 p.m., Monday throughFriday. This notice is issued under the Federal Food, Drug, and Cosmetic Act (secs.515(d), 520(h), 90 Stat. 554-555, 571 (21 U.S.C. 360e(d), 360j(h))) andunder authority delegated to the Commissioner of Food and Drugs (21 CFR5.10) and redelegated to the Director, Center for Devices and RadiologicalHealth (21 CFR 5.53).<ITAG tagnum="21">Dated: April 7, 1989. </ITAG><ITAG tagnum="6">Walter E. Gundaker, </ITAG><ITAG tagnum="4">Acting Deputy Director, Center for Devices and Radiological Health.</ITAG><ITAG tagnum="40">[FR Doc. 89-9136 Filed 4-17-89; 8:45 am] </ITAG><ITAG tagnum="68">BILLING CODE 4160-01-M</ITAG></ITAG></ITAG></TEXT></DOC>